Search filters

Filters
Clear All

Phase

  • 9
  • 12
  • 14
  • 1
  • 13
  • 58
  • 27
  • 1
  • 3
  • 54

Found 58 Menstruation trials

A listing of Menstruation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 2
This is a multicenter, exploratory, open-label study to explore the efficacy and/or pharmacodynamic effect, PK, safety, and tolerability of mavacamten in approximately 35 ambulatory participants with symptomatic HFpEF and elevated cTnI and/or elevated NT-proBNP as defined in inclusion/exclusion criteria. The study will include an up to 7-week screening period (with …
99 years or below
All genders
Phase 2
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
99 years or below
All genders
The purpose of this registry is to collect real-time data for those patients who have aortic disease of their ascending (top) aorta and the aortic arch (curved area where the vessels that supply the brain with blood). The current treatment requires open surgery or a hybrid procedure (open surgery with …
 Study Evaluating the Efficacy of Synergo  Radiofrequency-Induced Thermochemotherapy Effect (RITE) with Mitomycin C (Synergo  RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC)
18 years - 99 years
All genders
Phase 3
The objectives of the study are to determine the efficacy and safety of Synergo® RITE and mitomycin C (MMC) in the treatment of carcinoma in situ (CIS) non-muscle invasive bladder cancer in adult patients who didn't respond to 2 courses of treatment with Bacillus Calmette-Guérin (BCG) installations. The Synergo® system …
99 years or below
All genders
Phase 3
This is a randomized, double-blind, placebo-controlled, multicenter study in patients with primary cold agglutinin disease (CAgD) without a recent history of blood transfusion. Eligible patients will receive study drug (BIVV009 or placebo) and undergo safety and efficacy assessments for 6 months (26 weeks) during Part A. Following completion of the …
 Randomized Study of Cranial Blocks for Postoperative Anesthesia to Reduce Pain and Postoperative Opioid Usage
18 years - 99 years
All genders
The research study is being conducted to look at the effectiveness of analgesia (pain medication) by scalp nerve block with various medications that will help doctors to more effectively control pain after surgery and for a longer period of time. 
99 years or below
All genders
The study is being conducted to understand why the skeletal muscle of patients with Heart Failure with Preserved Ejection Fraction (HFpEF) does not work as well as the muscle of individuals without heart failure. This study seeks to understand whether the problem is with blood and oxygen delivery to the …
99 years or below
All genders
Phase 1
Patients with known or suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 20 …
99 years or below
All genders
Phase 2
The main purpose of this research study is to test the safety and tolerability of PCS499 when given to individuals at a dose of 300 mg, twice a day for 1 week followed by giving PCS499 to individuals at a dose of 900 mg, twice a day, for remaining treatment …
99 years or below
All genders
Phase 2
Modification #2 Feb 15, 2021: Title of protocol changed and phase changed from phase 2 to phase 2b. Changes in timing of selected activities, addition of labs (ESR, coagulation tests), the PRO sub-study and a COVID related consent for remote monitoring. IB updated to Edition 5. Modification #1 May 2020: …